Related Experiment Video
Updated: May 22, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
Published on: October 23, 2020
Prognostic factors for survival after allogeneic transplantation in acute myeloid leukemia in Iran using censored
Maryam Tatari1, Amir Kasaeian2,3,4, Amir-Hossein Mousavian5,6
1Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Hematopoietic stem cell transplantation (HSCT) emerged over sixty years ago as a groundbreaking and potentially curative treatment for patients with acute myeloid leukemia (AML) who were not responding to chemotherapy. In this study, we aimed to investigate prognostic factors for survival after allo-HSCT in AML patients. This retrospective cohort study was carried out using data from 742 adult AML patients underwent allo-HSCT. we analysis prognostic factors for survival after allo-HSCT with censored quantile regression model. The 5-year OS, DFS and GRFS rates were 58, 53, and 30%, respectively. OS for recipients older than 35 years was 0.95 and 1.12 years lower than that for recipients under 35 years in the 25th and 40th percentiles, respectively. Compared to patients in their CRІ, those with CRІІІ disease experienced a decrease in OS at the 25th and 40th percentiles by 1.72 and 3.72 years, respectively. Moreover, OS for ABO matched patients was 0.92 and 1.29 years longer than that of patients with an ABO major mismatch. This study could assist oncologists and hematologists in understanding the prognostic factors affecting patient survival across various survival ranges, thereby potentially extending patients' lifespans.
Hematopoietic stem cell transplantation (HSCT) emerged over sixty years ago as a groundbreaking and potentially curative treatment for patients with acute myeloid leukemia (AML) who were not responding to chemotherapy. In this study, we aimed to investigate prognostic factors for survival after allo-HSCT in AML patients. This retrospective cohort study was carried out using data from 742 adult AML patients underwent allo-HSCT. we analysis prognostic factors for survival after allo-HSCT with censored quantile regression model. The 5-year OS, DFS and GRFS rates were 58, 53, and 30%, respectively. OS for recipients older than 35 years was 0.95 and 1.12 years lower than that for recipients under 35 years in the 25th and 40th percentiles, respectively. Compared to patients in their CRІ, those with CRІІІ disease experienced a decrease in OS at the 25th and 40th percentiles by 1.72 and 3.72 years, respectively. Moreover, OS for ABO matched patients was 0.92 and 1.29 years longer than that of patients with an ABO major mismatch. This study could assist oncologists and hematologists in understanding the prognostic factors affecting patient survival across various survival ranges, thereby potentially extending patients' lifespans.
More Related Videos
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Related Concept Videos
Cancer Survival Analysis
Comparing the Survival Analysis of Two or More Groups
Kaplan-Meier Approach
Introduction To Survival Analysis
The primary goal of survival analysis is to estimate survival time—the time...
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Assumptions of Survival Analysis